Q1. The pharmaceutical landscape is rapidly evolving beyond traditional modalities. From your perspective, what factors are driving the growing demand for multi-modality CDMOs that can support small molecules, peptides, and advanced therapies under one umbrella?
John Lee: What is changing is not simply the number of modalities but the way pipelines are built. A sponsor may have small molecules, peptides, and viral vector-enabled programs in parallel, each with distinct CMC risk profiles. The value of a multi-modality CDMO is reducing fragmentation. Separate vendors can mean separate analytical strategies, tech-transfer packages, quality systems, and change-control logic. A multi-modality CDMO is valuable when it reduces those handoffs while preserving deep expertise for each platform.
Q2. Small molecules continue to account for a significant portion of approved therapeutics. How do you see their role evolving within a multi-modality manufacturing ecosystem over the next decade?
Steve Barr: Small molecules remain central, but the work is becoming more technically demanding. More programs involve high potency, complex chiral control, ADC payloads and linkers, flow chemistry, biocatalysis, or challenging impurity profiles. In a multi-modality network, small molecule teams bring mature disciplines: process safety, purge strategy, validation, lifecycle management, and commercial cost control. Those capabilities are increasingly important as newer modalities face the same pressure to become scalable and reliable.
Q3. As manufacturing networks become more diverse, what operational challenges do CDMOs face when integrating different therapeutic modalities across multiple sites and technologies?
Declan Hannigan: The operational challenge is integration without homogenization. A small-molecule site, a peptide operation, and a viral vector facility each have different cycle times, raw material risks, analytical methods, and deviation patterns.. CDMOs need common governance for quality, change control, tech transfer, and data, while maintaining enough local authority for site teams to solve modality-specific problems quickly.
Q4. Cell and gene therapies require highly specialized manufacturing capabilities. What lessons from the advanced therapies sector can be applied to improve flexibility and innovation across broader CDMO operations?
John Lee: Advanced therapies teach us that comparability cannot be an afterthought. In viral vectors, a late change to the cell line, plasmid source, purification, or analytical method can pose regulatory and clinical risks. The broader lesson is to define critical quality attributes, potency assays, and scale-up assumptions early. Flexibility comes from platform design, closed processing, and data continuity, not from redesigning the process after pivotal studies begin.
Q5. Peptides are experiencing remarkable growth due to their therapeutic potential. How is this trend influencing investment decisions and capacity planning within modern CDMO organizations?
Steve Barr: Peptide demand is being reshaped by the GLP-1 era, but the manufacturing challenge goes beyond synthesis capacity. Long or modified sequences can create coupling, aggregation, impurity, and purification challenges. Thus, investment has to cover SPPS, LPPS, hybrid approaches, chromatography, analytical development, and release testing. For many programs, the bottleneck is not making crude peptide; it is achieving consistent purity, yield, and cost at scale.
Q6. Many pharmaceutical companies are looking for end-to-end development and manufacturing partners. How important is operational integration in delivering seamless support from early development through commercial production?
Declan Hannigan: End-to-end support matters only if early decisions are made with the commercial process in mind. A route that looks attractive in Phase I may later pose challenges for solvent, impurity purge, validation, or waste management. Operational integration means that development, analytics, quality, engineering, procurement, and manufacturing align on the control strategy before tech transfer. That reduces rework, accelerates tech transfer and gives sponsors a clearer line of sight from clinical supply to launch.
Q7. As advanced therapies move toward commercialization, scalability remains a major concern. What innovations do you believe will have the greatest impact on improving manufacturing efficiency and scalability in the coming years?
John Lee: For advanced therapies, scalability is increasingly about process control challenge rather than a capacity issue. The biggest gains will come from improved producer cell lines, suspension platforms, closed and automated processing, high-throughput analytics, and stronger digital batch visibility. At commercial scale, small improvements in yield, full-to-empty ratio, potency consistency, or batch success rate can materially affect cost of goods, facility utilization, and patient access.
Q8. With multiple modalities often requiring distinct technologies and expertise, how can CDMOs ensure knowledge sharing and collaboration across business units without compromising specialization?
Steve Barr: Knowledge sharing should focus on failure modes, not general awareness. Peptide scientists team do not need to become viral vector experts, or vice versa, but both can learn from how the other manages impurity control, deviation closure, containment, analytical robustness, or customer governance. The right mechanisms include cross-business technical reviews, shared root-cause learning, common tech-transfer templates, and senior scientific forums that protect specialization while moving practical lessons across the network.
Q9. Digitalization and data-driven manufacturing are transforming pharmaceutical production. What role do technologies such as automation, and advanced analytics, play in enabling successful multi-modality operations?
Declan Hannigan: Digitalization truly enhances how we make decisions in the lab and on the manufacturing floor. Electronic batch records help prepare for releases more smoothly and reduce documentation delays. Advanced analytics can catch process issues early before they become larger deviations.. For multi-site CDMOs, shared data models make it easier to compare performance, risks, and customer insights across different technologies, creating a more unified and transparent view.
Q10. Regulatory expectations continue to evolve across biologics, cell and gene therapies, and traditional pharmaceuticals. How can CDMOs maintain compliance while remaining agile enough to support emerging therapeutic platforms?
John Lee: Agility is rooted in a well-structured regulatory framework, not just quick thinking. Emerging platforms still need clear CMC narratives, validated or qualified methods, traceability of raw materials, plans for comparability, and deviation control. A CDMO can move quickly when its quality system is standardized enough to provide control, but flexible enough to accommodate modality-specific expectations. In cell and gene therapy, early alignment on potency, vector characterization, and process comparability can determine whether scaling speeds up or slows down the program.
Q11. Partnership models between sponsors and CDMOs are changing. What qualities do pharmaceutical companies increasingly seek in strategic manufacturing partners, and how can CDMOs differentiate themselves in a competitive market?
Steve Barr: Sponsors increasingly choose partners based on risk reduction, not capacity alone. They want technical judgment, audit readiness, realistic timelines, supply-chain transparency, and candid escalation when a program changes. CDMOs differentiate themselves by demonstrating how they manage complexity: difficult chemistry, purification, analytical testing, strong quality systems, and commercial launch readiness. The strongest partnerships are built on shared decisions about risk, cost, timeline, and future scalability.
Q12. From a manufacturing excellence perspective, what best practices should CDMOs adopt to effectively balance quality, speed, cost efficiency, and sustainability across diverse product portfolios?
Declan Hannigan: Manufacturing excellence is all about making trade-offs clear, helping us see the bigger picture. While quality is always a top priority, increasing speed becomes easier when we truly understand our processes, reducing the need for rework. Costs and sustainability also benefit from higher yields, solvent recovery, waste reduction, energy efficiency, and continuous processing when technically feasible. No matter the project, CDMOs thrive with phase-appropriate development, careful tech transfer, consistent performance management, and a culture that views deviations as opportunities to learn rather than just problems to fix.
Q13. Looking ahead to 2030, what do you believe will define a successful multi-modality CDMO, and which capabilities will become essential for long-term competitiveness?
John Lee: By 2030, a successful multi-modality CDMO will be defined by its ability to make advanced therapies commercially practical, not just technically possible. That means scalable platforms, strong potency and characterization tools, comparability strategies, and resilient critical-material supply. The differentiator will be execution: converting complex, variable processes into reproducible manufacturing systems that can support clinical progress, commercial launch, and reliable patient access.
Steve Barr: By 2030, customers will expect specialized technical depth without managing three disconnected vendor models. For small molecules and peptides, the decisive capabilities will be complexity management, purification efficiency, process safety, impurity control, and cost-effective scale. The winning CDMO will integrate project governance, analytics, quality, and supply planning across modalities while preserving the scientific depth needed to solve hard chemistry and manufacturing problems.
Declan Hannigan: By 2030, the differentiator will be how well a CDMO operates its network as a single system. Customers will expect common quality standards, transparent data, disciplined escalation, and reliable tech transfer across regions, without losing site-level accountability. Multi-modality operations will require leaders who can manage varying cycle times, regulatory expectations, and supply risks while ensuring execution feels coordinated rather than fragmented.
Q14. If you could offer one piece of advice to biopharma companies evaluating CDMO partnerships for future pipelines that may span multiple therapeutic modalities, what would it be?
John Lee: My advice is to evaluate the partner’s path to commercialization, not just its fit for the next milestone. In advanced therapies, early choices about cell line, vector platform, analytics, raw materials, and comparability can either preserve or limit future options. A strong CDMO should help sponsors avoid decisions that get a program to IND quickly but create risk for pivotal studies, validation, or launch.
Steve Barr: I would advise sponsors to assess how a CDMO thinks, not just what equipment it owns. Ask where the real risks lie: impurity control, purification yield, analytical readiness, containment, cost of goods, or supply continuity. A strong partner will be transparent about trade-offs and help preserve options as the program evolves. For multi-modality pipelines, judgment is often as important as capacity.
Declan Hannigan: My advice is to closely examine the execution culture. Capability slides rarely show what happens when a deviation occurs, a raw material is delayed, or a tech transfer reveals gaps. Ask who owns decisions, how risks are escalated, and how data is shared across sites. Multi-modality pipelines create complexity; the right CDMO will make that complexity visible, manageable and aligned to the sponsor’s priorities under pressure.
Thank you to our distinguished panelists for sharing their expertise and valuable perspectives. And thank you to our readers for engaging with this important industry conversation.
Read the full article — it's free
Register with Pharma Focus America to unlock expert insights, research articles and in-depth industry analysis.
